{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"No relapse/progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Relapse/progression at 12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"PFS is defined as the duration from transplant to time of first progression, death, relapse after CR, or the date the patient was last known to be in remission.\n\nResponse will be assessed per the International Myeloma Working Group (IMWG) Response Criteria.","groups":[{"description":"Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0","id":"OG000","title":"V-BEAM + Stem Cell Infusion"}],"paramType":"NUMBER","populationDescription":"Two participants without evaluable responses due to early mortality were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"Median follow-up of 6 months (range: 6.0-12.0 months)","title":"Number of Participants With Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"participants"}